Implant Sciences Demonstration of Quantum Sniffer Explosive Detection Device Now Available on Internet WebcastWAKEFIELD, Mass.--(BUSINESS WIRE)--Nov. 24, 2004--Implant Sciences Corporation (AMEX: "IMX", "IMX.WS"), announced today that the Quantum Sniffer explosives detection device demonstration is now available for public viewing on the internet. The demonstration can now be accessed at www.runonideas.com or www.implantsciences.com.
Recently the Company delivered 15 hand-held bomb detectors, called Quantum Sniffers, to the U.S. Army and the U.S. Navy. Investors will see a demonstration of the Quantum Sniffer detecting actual explosive material. The demonstration will also function as an important sales tool to show how non-military agencies, such as bomb squads and local law enforcement agencies in the United States and in terrorist hot spots across the world, can use the Quantum Sniffer to help protect their communities and infrastructure.
The Global Military Aircraft Market 2011-2021
Dr. Anthony J. Armini, CEO of Implant Sciences Corporation, stated, "This web-based demonstration should provide the investment community and potential customers the opportunity to have a greater understanding of our explosives detection technology. I believe that our Quantum Sniffer technology could play an important role in detecting bombs and bomb materials both domestically and throughout the world."
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for national security, medicine, and industry. Under development are portable and bench-top trace element detection devices to identify explosives, narcotics and other toxic materials. The Company has also received government grants from the U.S. Army, Navy and Air Force, and the Transportation Security Administration to adapt the Company's explosive detection technology to a wide number of security requirements.
Using its proprietary ion implantation and thin film coating technologies, Implant Sciences has a sophisticated production line that modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby substantially increasing the life of the implants. The Company also manufactures and markets radioactive and non-radioactive products for medical use, including radioactive seeds for treating prostate cancer that are distributed throughout the United States by its own direct sales force. In parallel with the production of these seeds, it is also developing additional brachytherapy products for the treatment of breast, eye, and other cancers.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect", "should" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Aurelius Consulting Group
Dave Gentry, 407-644-4256
Implant Sciences Corporation
David C. Volpe, 508-523-3141
The Investor Relations Group
Mike Graff/Janet Vasquez, 212-825-3210
Source : Implant Sciences Corporation